Counterfeit Ozempic: what FDA’s warning says to check
FDA has found counterfeit OZEMPIC in the U.S. supply chain. Its latest dated update identifies a counterfeit using a lot number that also belongs to authentic product, so a lot-number match alone cannot establish whether a pen is genuine.2
On this page
Read the correct update
FDA’s counterfeit OZEMPIC warning is a living notice with more than one dated incident. The latest dated update on the page checked for this article is December 5, 2025. Earlier sections describe other lot and serial information. Do not combine details from different incidents into one invented authentication rule.
The December update reports counterfeit OZEMPIC injection labeled with lot PAR1229. FDA explicitly says that this is also an authentic lot number. That makes the usual advice to “check the lot” incomplete: a counterfeiter can copy a real lot identifier.2
The agency provides a packaging comparison for this incident. On the counterfeit pen, the EXP/LOT text appears to the left of the expiration date and lot number. On the authentic pen, that text is above them. FDA tells patients not to use a pen with the counterfeit placement described in that notice.2
What the warning does and does not prove
The notice is useful because it gives a concrete sign attached to a known incident. It is not a universal test that authenticates every pen on the market. A product that does not show this particular discrepancy has not therefore passed a laboratory or supply-chain check.
FDA also says patients who received the PAR1229 product through the Novo Nordisk Patient Assistance Program may continue using it because that product is authentic. Omitting that qualification would incorrectly turn a counterfeit warning into a warning against every product carrying the lot number.2
The December update reports that testing of the seized products was underway to determine composition and safety risks. A packaging comparison therefore should not be presented as a way for consumers to determine what a suspicious pen contains.2
A cheap price, a familiar-looking box or a photograph of a genuine pen is not a substitute for verifying where the medication was dispensed. A review page can explain a provider’s stated process, but it cannot authenticate the supply a particular patient receives.
Why the dispensing route matters
FDA advises patients to obtain OZEMPIC with a valid prescription through state-licensed pharmacies and to inspect the product for signs of counterfeiting. It directs pharmacies to authorized distributors and says pharmacists with authenticity concerns should contact the manufacturer.2
The notice also explains that the counterfeit units had entered the legitimate U.S. drug supply chain after distribution outside the manufacturer’s authorized supply chain. This is why the identity of the pharmacy and the ability to investigate a shipment matter even when a box looks familiar.
For an online program, ask which pharmacy will dispense the prescription and how to contact that pharmacy directly. If the platform will not identify the dispenser before enrollment, ask when that information becomes available and how a problem with a delivery is handled. A customer-support chat is useful only if it can route the issue to the responsible pharmacy.
If a product looks suspicious
Keep the packaging and prescription details available for the pharmacist and prescriber. Describe the discrepancy precisely and use the current FDA notice as the reference. The relevant issue might be the pen label, the shipping documentation or a mismatch between the named pharmacy and the one you expected. The Ozempic pen guide explains the legitimate pen formats; matching a format still does not authenticate an individual pen.
Follow the specific FDA instruction not to use a product that matches its counterfeit information. Ask the pharmacy and prescribing clinician how to verify the supply and maintain care while the question is resolved. Do not try to identify an unknown medicine by experimenting with it.
FDA directs patients and healthcare professionals to MedWatch for reporting adverse events or product-quality problems. Reporting a suspected problem is different from proving that a product is counterfeit; the report gives the agency information to investigate.2
If symptoms suggest a medical emergency, seek emergency care. A product investigation and an urgent medical assessment are different needs, and one should not wait for the other.
Counterfeit is not a synonym for compounded
A counterfeit claims to be an authentic product when it is not. A compounded medicine is a different category: it is not an FDA-approved version of the branded drug and should not be advertised as though it were. FDA discusses concerns about both, but that does not make the terms interchangeable.1
The difference helps you ask the right question. For a branded pen, authenticity and supply chain are central. For a compounded preparation, ingredient identity, dispensing responsibility and the absence of FDA approval need clear explanation. In either case, the price is only one part of the decision.
Use FDA’s original warning and images for the current incident details. This article explains how to read the notice; it does not replace the agency’s updates or offer a complete list of every counterfeit in circulation.
Related reading
Read next
Sources
A reference, not medical advice, and not a substitute for your prescriber or pharmacist. If you think you are having a medical emergency, call your local emergency number.